The Evaluation of Methylated Septin 9 in Blood Plasma and Tissue Biopsies for the Early Detection for Asymptomatic Colon Cancer
DOI:
https://doi.org/10.3889/oamjms.2021.7156Keywords:
Colon cancer, Septin 9 gene, Early diagnosis, Septin 9Abstract
The purpose of this study was to assess the utility of the SEPT9 genetic marker in the early detection of colon cancer patients. A case-control study was conducted on forty newly diagnosed colon cancer patients. The study was done between March 2019 and January 2020, patients from the Gastroenterology and Liver Education Hospital, Al-imamain Al-Kadhimain Medical City, and Baghdad Teaching Hospital were recruited. Colon cancer patients' mean age ± standard deviation was 54.4 ± 10.79 years while the age ± standard deviation of the mean of the control group was 55.1±8.54 years. For septin9 tissue methylation of the controls was done on the non-malignant tissues of the same patients.
This study concluded that the percentage of Septin 9 (SEPT9) in the tissue of patients with colon cancer (CC) was the highest value, which is more significant than that of the serum of CC patients. Both of these groups were significantly higher than the percentage of SEPT9 methylation of control tissue and serum.
Non-significant differences were obtained in the levels of CEA and CA19-9 between CC patients and controls.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Wu D, Zhou G, Jin P, Zhu J, Li S, Wu Q, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J Mol Diagn. 2016;18:535-45. https://doi.org/10.1016/j.jmoldx.2016.02.005 PMid:27133379 DOI: https://doi.org/10.1016/j.jmoldx.2016.02.005
Fu B, Yan P, Zhang S, Lu Y, Pan L, Tang W, et al. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis Markers. 2018;2018:6437104. https://doi.org/10.1155/2018/6437104 PMid:29849824 DOI: https://doi.org/10.1155/2018/6437104
Bresalier RS, Kopetz S, Brenner DE. Blood-based tests for colorectal cancer screening: Do they threaten the survival of the FIT test? Dig Dis Sci. 2015;60(3):664-71. https://doi.org/10.1007/s10620-015-3575-2 PMid:25680874 DOI: https://doi.org/10.1007/s10620-015-3575-2
Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruïne AP, Carvalho B, et al. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: Implications for prognosis. Ann Oncol. 2013;24(8):2048-56. https://doi.org/10.1093/annonc/mdt076 PMid:23532114 DOI: https://doi.org/10.1093/annonc/mdt076
Sun J, Fei F, Zhang M, Li Y, Zhang X, Zhu S, Zhang S. The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer. 2019;19(1):450. https://doi.org/10.1186/s12885-019-5663-8 PMid:31088406 DOI: https://doi.org/10.1186/s12885-019-5663-8
Ebert MP, Mooney SH, Tonnes-Priddy L, Lograsso J, Hoffmann J, Chen J, et al. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia. 2005;7(8):771-8. https://doi.org/10.1593/neo.05235 PMid:16207479 DOI: https://doi.org/10.1593/neo.05235
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317-25. https://doi.org/10.1136/gutjnl-2012-304149 PMid:23408352 DOI: https://doi.org/10.1136/gutjnl-2012-304149
Shen N, Wang T, Li D, Zhu Y, Xie H, Lu Y. Hypermethylation of the SEPT9 gene suggests significantly poor prognosis in cancer patients: A systematic review and meta-analysis. Front Genet. 2019;10:887. https://doi.org/10.3389/fgene.2019.00887 PMid:31608117 DOI: https://doi.org/10.3389/fgene.2019.00887
Verdier-Pinard P, Salaun D, Bouguenina H, Shimada S, Pophillat M, Audebert S, et al. Septin 9-i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments. Sci Rep. 2017;7:44976. https://doi.org/10.1038/srep44976 PMid:28338090 DOI: https://doi.org/10.1038/srep44976
Wang Y, Chen PM, Liu RB. Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection. World J Gastrointest Oncol. 2018;10(1):15-22. https://doi.org/10.4251/wjgo.v10.i1.15 PMid:29375744 DOI: https://doi.org/10.4251/wjgo.v10.i1.15
Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54(2):414-23. https://doi.org/10.1373/clinchem.2007.095992 Mid:18089654 DOI: https://doi.org/10.1373/clinchem.2007.095992
Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 2008;3(11):e3759. https://doi.org/10.1371/journal.pone.0003759 PMid:19018278 DOI: https://doi.org/10.1371/journal.pone.0003759
deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55:1337-46. https://doi.org/10.1373/clinchem.2008.115808 PMid:19406918 DOI: https://doi.org/10.1373/clinchem.2008.115808
Björkman K, Jalkanen S, Salmi M, Mustonen H, Kaprio T, Kekki H, et al. A prognostic model for colorectal cancer based on CEA and a 48-multiplex serum biomarker panel. Sci Rep. 2021;11(1):4287. https://doi.org/10.1038/s41598-020-80785-1 PMid:33619304 DOI: https://doi.org/10.1038/s41598-020-80785-1
Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep. 2018;8(1):2732. https://doi.org/10.1038/s41598-018-21048-y PMid:29426902 DOI: https://doi.org/10.1038/s41598-018-21048-y
Vogelstein B, Gillespie D. Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci USA. 1979;76(2):615-9. PMid:284385 DOI: https://doi.org/10.1073/pnas.76.2.615
Norman G. Likert scales, levels of measurement and the “laws” of statistics. Adv Health Sci Educ Theory Pract. 2010;15(5):625-32. https://doi.org/10.1007/s10459-010-9222-y PMid:20146096 DOI: https://doi.org/10.1007/s10459-010-9222-y
Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med. 2013;4(2):627-35. PMid:24009950
Meng C, Yin X, Liu J, Tang K, Tang H, Liao J. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis. PLoS One. 2018;13(11):e0207039. https://doi.org/10.1371/journal.pone.0207039 Mid:30458003 DOI: https://doi.org/10.1371/journal.pone.0207039
Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepatogastroenterology. 1999;46(26):905-8. PMid:10370636
Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, Bijedic N, Bjelogrlic I, Gogov B, et al. Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med Arch. 2013;67(6):397-401. https://doi.org/10.5455/medarh.2013.67.397-401 PMid:25568506 DOI: https://doi.org/10.5455/medarh.2013.67.397-401
Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, et al. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: A BRAF-mutant subset with high CA 19-9 level and poor outcome. Br J Cancer. 2018;118(12):1609-16. https://doi.org/10.1038/s41416-018-0115-9 PMid:29872151 DOI: https://doi.org/10.1038/s41416-018-0115-9
Vočka M, Langer D, Fryba V, Petrtyl J, Hanus T, Kalousova M, et al. Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer. Int J Biol Markers. 2019;34(3):292-301. https://doi.org/10.1177/1724600819866202 PMid:31578137 DOI: https://doi.org/10.1177/1724600819866202
Kim NH, Lee MY, Park JH, Park DI, Sohn CI, Choi K, et al. Serum CEA and CA 19-9 levels are associated with the presence and severity of colorectal neoplasia. Yonsei Med J. 2017;58(5):918-24. https://doi.org/10.3349/ymj.2017.58.5.918 PMid:28792134 DOI: https://doi.org/10.3349/ymj.2017.58.5.918
Xie L, Jiang X, Li Q, Sun Z, Quan W, Duan Y, et al. Diagnostic value of methylated Septin9 for colorectal cancer detection. Front Oncol. 2018;8:247. https://doi.org/10.3389/fonc.2018.00247 PMid:30013949 DOI: https://doi.org/10.3389/fonc.2018.00247
Alexander JC, Silverman NA, Chretien PB. Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA. 1976;235(18):1975-9. https://doi.org/10.1001/jama.1976.03260440027017 PMid:56468 DOI: https://doi.org/10.1001/jama.235.18.1975
Fukuda I, Yamakado M, Kiyose H. Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services. J Med Syst. 1998;22(2):89-93. Mid:9571515 DOI: https://doi.org/10.1023/A:1022643102208
Huang CS, Chen CY, Huang LK, Wang WS, Yang SH. Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients who smoke. PLoS One. 2020;15(6):e0233687. https://doi.org/10.1371/journal.pone.0233687 PMid:32502149 DOI: https://doi.org/10.1371/journal.pone.0233687
Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res. 2002;8(1):156-64. PMid:11801553
Zhang SY, Lin M, Zhang HB. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma. Int J Clin Exp Pathol. 2015;8(8):9404-9. PMid:26464695
Sun J, Zheng MY, Li YW, Zhang SW. Structure and function of Septin 9 and its role in human malignant tumors. World J Gastrointest Oncol. 2020;12(6):619-31. https://doi.org/10.4251/wjgo.v12.i6.619 Mid:32699577 DOI: https://doi.org/10.4251/wjgo.v12.i6.619
Downloads
Published
How to Cite
License
Copyright (c) 2020 Ahmed Ageeb Kassid, Omar F. Abdul-Rasheed, Nawal Mehdi AlKhalidy (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
